{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:07:37Z","timestamp":1794546457966,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-025-04193-6","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:03:20Z","timestamp":1770113000000},"page":"1095-1104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-7054","authenticated-orcid":false,"given":"Richard S.","family":"Finkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5088-6012","authenticated-orcid":false,"given":"Charlotte J.","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1610-0164","authenticated-orcid":false,"given":"Maria del Mar","family":"Garcia Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-0819","authenticated-orcid":false,"given":"Jacqueline","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D.","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5081-4689","authenticated-orcid":false,"given":"Emily","family":"Boesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Inra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Littauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihee","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Monine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raechel","family":"Farewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1807-1602","authenticated-orcid":false,"given":"Stephanie","family":"Fradette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"4193_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"BS Russman","year":"2007","unstructured":"Russman, B. S. Spinal muscular atrophy: clinical classification and disease heterogeneity. J. Child Neurol. 22, 946\u2013951 (2007).","journal-title":"J. Child Neurol."},{"key":"4193_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","volume":"12","author":"MA Farrar","year":"2015","unstructured":"Farrar, M. A. & Kiernan, M. C. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics 12, 290\u2013302 (2015).","journal-title":"Neurotherapeutics"},{"key":"4193_CR3","doi-asserted-by":"crossref","unstructured":"Darras, B. T., Jones, H. R. J., Ryan, M. M. & De Vivo, D. C. in Neuromuscular Disorders of Infancy, Childhood, and Adolescence: a Clinician\u2019s Approach (eds Darras, B. T. et al.) 117\u2013145 (Academic Press, 2015).","DOI":"10.1016\/B978-0-12-417044-5.00008-1"},{"key":"4193_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","volume":"4","author":"MD Mailman","year":"2002","unstructured":"Mailman, M. D. et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet. Med. 4, 20\u201326 (2002).","journal-title":"Genet. Med."},{"key":"4193_CR5","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani, U. R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8, 1177\u20131183 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"4193_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold, W. D., Kassar, D. & Kissel, J. T. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51, 157\u2013167 (2015).","journal-title":"Muscle Nerve"},{"key":"4193_CR7","unstructured":"Biogen. Prescribing Information: SPINRAZA 12 mg solution for injection. Initial U.S. Approval: 2016 (revised April 2024) www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209531s013s014lbl.pdf (2024)."},{"key":"4193_CR8","unstructured":"Biogen Netherlands. Summary of Product Characteristics: Spinraza 12 mg solution for injection. First authorisation: 30 May 2021 (latest renewal 21 January 2022) www.ema.europa.eu\/en\/documents\/product-information\/spinraza-epar-product-information_en.pdf (2025)."},{"key":"4193_CR9","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras, B. T. et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology 92, e2492\u2013e2506 (2019).","journal-title":"Neurology"},{"key":"4193_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo, D. C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul. Disord. 29, 842\u2013856 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"4193_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4193_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625\u2013635 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4193_CR13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40120-024-00653-2","volume":"13","author":"T Hagenacker","year":"2024","unstructured":"Hagenacker, T. et al. Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis. Neurol. Ther. 13, 1483\u20131504 (2024).","journal-title":"Neurol. Ther."},{"key":"4193_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","volume":"68","author":"TO Crawford","year":"2023","unstructured":"Crawford, T. O. et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve 68, 157\u2013170 (2023).","journal-title":"Muscle Nerve"},{"key":"4193_CR15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras, B. T. et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 6, 932\u2013944 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4193_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213371","volume":"104","author":"I Cordts","year":"2025","unstructured":"Cordts, I. et al. Long-term dynamics of CSF and serum neurofilament light chain in adult patients with 5q spinal muscular atrophy treated with nusinersen. Neurology 104, e213371 (2025).","journal-title":"Neurology"},{"key":"4193_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-023-01551-8","volume":"11","author":"L Kong","year":"2023","unstructured":"Kong, L. et al. Boosting neuregulin 1 type-III expression hastens SMA motor axon maturation. Acta Neuropathol. Commun. 11, 53 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"4193_CR18","doi-asserted-by":"publisher","first-page":"eabb6871","DOI":"10.1126\/scitranslmed.abb6871","volume":"13","author":"L Kong","year":"2021","unstructured":"Kong, L. et al. Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci. Transl. Med. 13, eabb6871 (2021).","journal-title":"Sci. Transl. Med."},{"key":"4193_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/acn3.51562","volume":"9","author":"RS Finkel","year":"2022","unstructured":"Finkel, R. S. et al. Scientific rationale for a higher dose of nusinersen. Ann. Clin. Transl. Neurol. 9, 819\u2013829 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4193_CR20","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"},{"key":"4193_CR21","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","volume":"63","author":"G Acsadi","year":"2021","unstructured":"Acsadi, G. et al. Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study. Muscle Nerve 63, 668\u2013677 (2021).","journal-title":"Muscle Nerve"},{"key":"4193_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JND-221667","volume":"10","author":"RS Finkel","year":"2023","unstructured":"Finkel, R. S. et al. DEVOTE study exploring higher dose of nusinersen in spinal muscular atrophy: study design and part A results. J. Neuromuscul. Dis. 10, 813\u2013823 (2023).","journal-title":"J. Neuromuscul. Dis."},{"key":"4193_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti, G. et al. Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis. Orphanet J. Rare Dis. 16, 430 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"4193_CR24","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.lanepe.2024.100862","volume":"39","author":"R G\u00fcnther","year":"2024","unstructured":"G\u00fcnther, R. et al. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study. Lancet Reg. Health Eur. 39, 100862 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"4193_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02769-4","volume":"18","author":"A \u0141usakowska","year":"2023","unstructured":"\u0141usakowska, A. et al. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience. Orphanet J. Rare Dis. 18, 230 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"4193_CR26","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870\u2013881 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"4193_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"4193_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E. et al. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul. Disord. 28, 103\u2013115 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"4193_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel, R. S. et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul. Disord. 28, 197\u2013207 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"4193_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/21678421.2012.762930","volume":"14","author":"JD Berry","year":"2013","unstructured":"Berry, J. D. et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 162\u2013168 (2013).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."}],"updated-by":[{"DOI":"10.1038\/s41591-026-04415-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04193-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:34:53Z","timestamp":1777008893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04193-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4193"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04193-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04415-5","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04415-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.F. reports receiving grant support (institution) from Biogen, Dyne, Genentech, Genethon, Italfarmaco, Novartis, Roche, Sarepta and Scholar Rock; royalties from the Children\u2019s Hospital of Philadelphia and Elsevier; advisory boards of Astellas, Biogen, Dyne, Genentech, Italfarmaco, Novartis, ReveraGen, Roche, Sarepta and Scholar Rock; honoraria and travel expenses from Novartis; patents from Roche; data safety monitoring boards of Ionis and University of Texas Southwestern; a leadership or fiduciary role for\n                      Neuromuscular Disorders\n                      (editorial board member),\n                      Journal of Neuromuscular Diseases\n                      (editorial board member) and the Pediatric Neuromuscular Clinical Research Network for SMA (steering committee member). T.O.C. reports funding from AveXis, Biogen, Catalyst, Cure SMA, Cytokinetics, Marathon, Novartis, Roche, Sarepta and the SMA Foundation; and consulting fees, advisory board and data safety monitoring board for Biogen. E.M. reports funding from AveXis, Biogen, Epirium, FamiglieSMA Italy, Ionis, Italian Telethon, NMD, Novartis, Roche and Scholar Rock. C.J.S. reports grant support from Actio Biosciences, Biogen and Roche; royalties from Elsevier; honoraria from Biogen, Genentech, Regeneron and Roche; travel to meetings support from Biogen, Regeneron and Roche; data safety monitoring board for Biogen; leadership or fiduciary role for the Peripheral Nerve Society (President); advisory boards for Cure SMA, the Charcot\u2013Marie\u2013Tooth Association, the Charcot\u2013Marie\u2013Tooth Research Foundation, the Kennedy\u2019s Disease Association, the Muscular Dystrophy Association and the Packard Center and Merkin Center; and receipt of drugs from Ionis and Roche. M.d.M.G.R. reports honoraria, expert testimony, travel expenses and data safety monitoring board support from Biogen. J.W.D. reports grant support (institution) from AMO Pharma, AnnJi Pharmaceutical, Astellas Gene Therapies, Avidity Biosciences, Biogen, CureSMA, Genentech, Ionis, the Muscular Dystrophy Association, the Myotonic Dystrophy Foundation, NMD Pharma, Novartis, Roche, Sanofi, Sarepta, Scholar Rock and the SMA Foundation; royalties (individual and institution) from Athena Diagnostics; and consulting fees from Avidity Biosciences, Biogen, Epirium Bio, Kate Therapeutics, Novartis, PepGen, Roche\/Genentech Pharmaceuticals, Sanofi, Sarepta Therapeutics, Scholar Rock, Solid Biosciences and Vertex Pharmaceuticals. J.M. reports grant support (institution) from Genentech and Scholar Rock; honoraria from Roche and Scholar Rock; and data safety monitoring boards for Argenx, Biogen, Roche and Scholar Rock. P.S., B.T., A.D.P., E.B., J.I., R.L., G.G., R. Foster, R. Farewell and S.F. are employees of Biogen and may hold stock. J.S. and M.M. were employees of Biogen at the time of contributing to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}